| 产品详情 |
| Edit |   |
|---|
| Product Name | Bortezomib, Free Base |
|---|
| Description | HPLC: ~99%; TLC: ~99%. Bortezomib is the active ingredient in the drug sold under the trade name Velcade®. This drug has been approved in at least one country to treat multiple myeloma. It is a potent (Ki, 0.6nM), specific and reversible proteasome inhibitor. There is not any significant inhibitory activity against other enzymes or receptors. In a study with the National Cancer Institute's panel of 60 human cell lines, Bortezomib showed a mean IC50 of 7nM as tested by SRB analysis. Bortezomib is active in preclinical models of human prostate cancer, while its effects on apoptosis versus angiogenesis are cell type dependent. Bortezomib caused comparable growth suppression in LNCaP-Pro5 and PC3M-Pro4 cells with an IC90 of 10nM. Bortezomib inhibits cell proliferation of H460 cells (Human non-small cell lung cancer cell lines) with an IC50 of 0.1uM. |
|---|
| Size | 5mg, 10mg, 25mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | Bortezomib, Free Base (Velcade, MG-341, PS-341, [(1S)-3-methyl-1-[[(2R)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic Acid) |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | B2572-02 |
|---|
| Price | |
|---|
| Order / More Info | Bortezomib, Free Base from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|